{"id":17735,"date":"2025-11-03T17:28:00","date_gmt":"2025-11-03T17:28:00","guid":{"rendered":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/"},"modified":"2025-11-03T17:28:00","modified_gmt":"2025-11-03T17:28:00","slug":"%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash","status":"publish","type":"post","link":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/","title":{"rendered":"\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a"},"content":{"rendered":"

\n<\/p>

2\u9879\u53e3\u5934\u62a5\u544a\u4e0e7\u9879\u58c1\u62a5\u5c55\u793a\u8fdb\u4e00\u6b65\u652f\u6301CARVYKTI\u00ae\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9886\u57df\u7684\u7814\u53d1\u5b9e\u529b<\/p>\n

\u5f02\u4f53<\/p>\n

CAR-T\u7ec6\u80de\u7597\u6cd5\u6cbb\u7597\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u7684\u9996\u6b21\u4eba\u4f53I\u671f\u4e34\u5e8a\u6570\u636e\u5c06\u4f5c\u4e3a\u53e3\u5934\u62a5\u544a\u91cd\u70b9\u5c55\u793a<\/p>\n

\n \u7f8e\u56fd\u65b0\u6cfd\u897f\u5dde\u8428\u9ed8\u585e\u7279<\/span>
\n 2025\u5e7411\u67084\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — \u5168\u7403\u7ec6\u80de\u7597\u6cd5\u9886\u5bfc\u8005\u4f20\u5947\u751f\u7269\u79d1\u6280\u516c\u53f8\uff08NASDAQ\uff1aLEGN\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5c06\u5728\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u4e0a\u901a\u8fc7\u4e24\u9879\u53e3\u5934\u62a5\u544a\u548c\u4e03\u9879\u58c1\u62a5\u91cd\u70b9\u5c55\u793aCARVYKTI\u00ae\uff08cilta-cel\uff1b\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\uff09\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9886\u57df\u7684\u6700\u65b0\u6570\u636e\u3002\u672c\u5c4a\u5e74\u4f1a\u5c06\u4e8e2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u56fd\u4f5b\u7f57\u91cc\u8fbe\u5dde\u5965\u5170\u591a\u4e3e\u884c\u3002<\/p>\n

\n

\n <\/a><\/p>\n

\n <\/p>\n<\/div>\n

\u9664CARVYKTI\u76f8\u5173\u6570\u636e\u5916\uff0c\u516c\u53f8\u8fd8\u5c06\u5c31\u5176\u5728\u7814\u7684\u9776\u5411CD20\/CD19\u53cc\u9776\u70b9\u901a\u7528\u578bCAR-\u03b3\u03b4T\u7ec6\u80de\u7597\u6cd5Lucar-G39D\u8fdb\u884c\u53e3\u5934\u62a5\u544a\uff0c\u8be5\u7597\u6cd5\u76ee\u524d\u6b63\u9488\u5bf9\u590d\u53d1\u6216\u96be\u6cbb\u6027B\u7ec6\u80de\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08NHL\uff09\u60a3\u8005\u5f00\u5c55\u4e34\u5e8a\u8bc4\u4f30\u3002<\/p>\n

\u4f20\u5947\u751f\u7269\u9996\u5e2d\u6267\u884c\u5b98\u9ec4\u9896\u535a\u58eb\u8868\u793a\uff1a”\u6211\u4eec\u5f88\u81ea\u8c6a\u5730\u770b\u5230\uff0c\u4eca\u5e74ASH\u5e74\u4f1a\u6240\u5c55\u793a\u7684\u6570\u636e\u66f4\u52a0\u6df1\u5165\u800c\u5e7f\u6cdb\uff0c\u8fd9\u5145\u5206\u4f53\u73b0\u4e86\u6211\u4eec\u7ec6\u80de\u7597\u6cd5\u9879\u76ee\u7684\u6301\u7eed\u521b\u65b0\u548c\u4e34\u5e8a\u5f71\u54cd\u529b\u3002\u672c\u5c4a\u4f1a\u8bae\u4e0a\u67099\u7bc7\u6458\u8981\u91cd\u70b9\u4ecb\u7ecd\u4e86CARVYKTI\uff0c\u8fd9\u4e9b\u7814\u7a76\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u5176\u5728\u7597\u6548\u6301\u4e45\u6027\u3001\u6301\u7eed\u4f18\u5316\u7684\u5b89\u5168\u6027\u7279\u5f81\u4ee5\u53ca\u771f\u5b9e\u4e16\u754c\u7597\u6548\u65b9\u9762\u7684\u8868\u73b0\uff0c\u4e3aCAR-T\u7597\u6cd5\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u66f4\u65e9\u7ebf\u6cbb\u7597\u4e2d\u7684\u5e94\u7528\u63d0\u4f9b\u4e86\u6709\u529b\u652f\u6301\u3002\u6b64\u5916\uff0cLucar-G39D\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\u6570\u636e\u5f70\u663e\u4e86\u6211\u4eec\u6b63\u5728\u6301\u7eed\u52aa\u529b\u5c06\u6211\u4eec\u7684\u7814\u53d1\u7ba1\u7ebf\u6269\u5c55\u5230\u9488\u5bf9B\u7ec6\u80de\u6076\u6027\u80bf\u7624\u60a3\u8005\u7684\u4e0b\u4e00\u4ee3\u5f02\u4f53\u7ec6\u80de\u7597\u6cd5\u3002”<\/p>\n

CARVYKTI\u662f\u5168\u7403\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e00\u7ebf\u6cbb\u7597\u7684\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u7684BCMA \u9776\u5411CAR-T\u7ec6\u80de\u7597\u6cd5\u3002\u76ee\u524dCARVYKTI\u5df2\u5728\u5168\u740314\u4e2a\u56fd\u5bb6\u4e0a\u5e02\uff0c\u8fc4\u4eca\u5df2\u6cbb\u7597\u8d85\u8fc79,000\u540d\u60a3\u8005\u3002<\/p>\n

\n \u4f1a\u8bae\u6458\u8981\u5217\u8868\u5982\u4e0b\uff1a\n <\/p>\n

\n ASH Presentations (December 6-9, 2025)\n <\/p>\n

\n

\n
\n CARVYKTI<\/span><\/p>\n


\n \u00ae
\n <\/span><\/p>\n

\n <\/p>\n

\n
\n \u6458\u8981\u7f16\u53f7
\n <\/span>\n <\/p>\n

\n
\n \u6807\u9898
\n <\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u4fe1\u606f
\n <\/span>\n <\/p>\n

\n \u6458\u8981#94<\/span>\n <\/p>\n

\n \u53e3\u5934\u62a5\u544a<\/span>\n <\/p>\n

\n Long-Term Progression-Free Survival Benefit With Ciltacabtagene Autoleucel in Standard-Risk Relapsed\/Refractory Multiple Myeloma<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a653. \u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a<\/span>\n <\/p>\n

\n \u4f18\u5316\u9aa8\u9ad3\u7624\u7684\u514d\u75ab\u7597\u6cd5\u2014\u2014\u4eceT\u7ec6\u80de\u9002\u5e94\u6027\u5230\u4e34\u5e8a\u7ed3\u5c40
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u53489:30 – \u4e0a\u534811:00
\u62a5\u544a\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u534810:15 – \u4e0a\u534810:30<\/span>\n <\/p>\n

\n \u6458\u8981#92<\/span>\n <\/p>\n

\n \u53e3\u5934\u62a5\u544a<\/span>\n <\/p>\n

\n Earlier Use of Ciltacabtagene Autoleucel (Cilta-cel) Is Associated With Better Immune Fitness and Stronger Immune Effects as Shown by Correlative Analysis of Peripheral Blood and the Bone Marrow Tumor Microenvironment (TME) From the CARTITUDE-4 Study\u00a0<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a653.\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a\u4f18\u5316<\/span>\n <\/p>\n

\n \u9aa8\u9ad3\u7624\u7684\u514d\u75ab\u7597\u6cd5\u2014\u2014\u4eceT\u7ec6\u80de\u9002\u5e94\u6027\u5230\u4e34\u5e8a\u7ed3\u5c40
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u53489:30 – \u4e0a\u534811:00
\u62a5\u544a\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u53489:45 – \u4e0a\u534810:00<\/span>\n <\/p>\n

\n \u6458\u8981 #2215
\u58c1\u62a5\u5c55\u793a<\/span>\n <\/p>\n

\n Effectiveness of Bridging Therapy Corresponds to Improved Outcomes After Ciltacabtagene Autoleucel: Phase 3 CARTITUDE-4 Study of Patients with Relapsed, Lenalidomide-Refractory Multiple Myeloma\u00a0<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a653.\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a\u58c1\u62a5\u5c55\u793a I
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0b\u53485:30 – \u665a\u4e0a7:30
<\/span>\n <\/p>\n

\n \u6458\u8981 #4046
\u58c1\u62a5\u5c55\u793a<\/span>\n <\/p>\n

\n Comparative Efficacy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone and Versus Belamaf, Pomalidomide, and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Previously Treated with 1\u20133 Prior Lines of Therapy Using a Matching-Adjusted Indirect Comparison<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a654.\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u836f\u7269\u6cbb\u7597\uff1a\u58c1\u62a5\u5c55\u793a II
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67087\u65e5\u665a\u4e0a6:00 – \u665a\u4e0a8:00
<\/span>\n <\/p>\n

\n \u6458\u8981 #3992
\u58c1\u62a5\u5c55\u793a<\/span>\n <\/p>\n

\n Population Differences and Comparative Efficacy Between Ciltacabtagene Autoleucel (Cilta-cel) From the CARTITUDE-1 Study and Anitocabtagene Autoleucel (Anito-cel) From the iMMagine-1 Study in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a653.\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a\u58c1\u62a5\u5c55\u793a II
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67087\u65e5\u665a\u4e0a6:00 – \u665a\u4e0a8:00
<\/span>\n <\/p>\n

\n \u6458\u8981 #5768
\u58c1\u62a5\u5c55\u793a<\/span>\n <\/p>\n

\n Quality-adjusted Survival Analysis of Neurologic Events with Ciltacabtagene Autoleucel (cilta-cel) vs Standard of Care (SOC) in Patients (Pts) with Lenalidomide-refractory Multiple Myeloma (MM) who Received 1\u20133 Prior Lines of Therapy (LOT):\u00a0CARTITUDE-4 Trial Population (Pop)<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a653.\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a\u58c1\u62a5\u5c55\u793a III
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67088\u65e5\u665a\u4e0a6:00 – \u665a\u4e0a8:00
<\/span>\n <\/p>\n

\n \u6458\u8981 #2214
\u58c1\u62a5\u5c55\u793a<\/span>\n <\/p>\n

\n Bridging Therapy Response and Low Pre-lymphodepletion Plasma Cell Burden Are Associated with Improved Safety and Efficacy Outcomes of Ciltacabtagene Autoleucel in Multiple Myeloma\u00a0<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a653.\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a\u58c1\u62a5\u5c55\u793a I
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0b\u53485:30 – \u665a\u4e0a7:30<\/span>\n <\/p>\n

\n \u6458\u8981 #4596
\u58c1\u62a5\u5c55\u793a<\/span>\n <\/p>\n

\n Real-world Incidence and Management of Non-ICANS Neurologic Events Following Ciltacabtagene Autoleucel in Multiple\u00a0Myeloma<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a907.\u7ed3\u5c40\u7814\u7a76\uff1a\u6d46\u7ec6\u80de\u75be\u75c5\uff1a\u58c1\u62a5\u5c55\u793a II
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67087\u65e5\u665a\u4e0a6:00 – \u665a\u4e0a8:00\u00a0<\/span>\n <\/p>\n

\n \u6458\u8981 #2411
\u58c1\u62a5\u5c55\u793a<\/span>\n <\/p>\n

\n Ciltacabtagene Autoleucel Out-of-Specification Manufacturing Outcomes Improve with Earlier Lines of Therapy<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a711. \u9020\u8840\u5e72\u7ec6\u80de\u3001CAR-T\u7ec6\u80de\u53ca\u5176\u4ed6\u7ec6\u80de\u6cbb\u7597\u4ea7\u54c1<\/span>\n <\/p>\n

\n \u7684\u91c7\u96c6\u4e0e\u5236\u5907\uff1a\u58c1\u62a5\u5c55\u793a I
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0b\u53485:30 – \u665a\u4e0a7:30
<\/span>\n <\/p>\n

\n
\n Allogeneic CAR-T Cell Therapy\u00a0\u5f02\u4f53CAR-T\u7ec6\u80de\u7597\u6cd5<\/span>\n <\/p>\n

\n
\n \u6458\u8981\u7f16\u53f7
\n <\/span>\n <\/p>\n

\n
\n \u6807\u9898
\n <\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u4fe1\u606f
\n <\/span>\n <\/p>\n

\n \u6458\u8981#266<\/span>\n <\/p>\n

\n \u53e3\u5934\u62a5\u544a<\/span>\n <\/p>\n

\n A Phase 1 Study of Lucar-G39D: A Novel Anti-CD20\/CD19 Dual-CAR Allogeneic Gamma Delta T Cells in Adults with Relapsed \/ Refractory B-Cell Non-Hodgkin Lymphoma (NHL)<\/span>\n <\/p>\n

\n
\n \u4f1a\u8bae\u540d\u79f0\uff1a704. \u7ec6\u80de\u514d\u75ab\u7597\u6cd5\uff1a\u65e9\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e0e\u6bd2\u6027\uff1a\u590d\u53d1\u6216<\/span>\n <\/p>\n

\n \u96be\u6cbb\u6027B\u7ec6\u80de\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u4e0e\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7684\u4e0b\u4e00\u4ee3CAR-T\u4e34\u5e8a\u8bd5\u9a8c
\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0b\u53482:00 – \u4e0b\u53483:30<\/span>\n <\/p>\n

\n
\n \u62a5\u544a\u65f6\u95f4\uff1a
\n 2025\u5e7412\u67086\u65e5\u4e0b\u53482:15 – \u4e0b\u53482:30
\n
\n <\/span>\n <\/p>\n<\/div>\n

\u00a0<\/p>\n

\n \u5173\u4e8e
\n CARVYKTI\u00ae\uff08cilta-cel\uff0c\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\uff09\n <\/p>\n

\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u662f\u4e00\u79cd\u9776\u5411B\u7ec6\u80de\u6210\u719f\u6297\u539f\uff08BCMA\uff09\u7684\u5d4c\u5408\u6297\u539f\u53d7\u4f53T\u7ec6\u80de\uff08CAR-T\uff09\u7597\u6cd5\uff0c\u4f7f\u7528\u5d4c\u5408\u6297\u539f\u53d7\u4f53\uff08CAR\uff09\u7684\u8f6c\u57fa\u56e0\u5bf9\u60a3\u8005\u81ea\u8eab\u7684T\u7ec6\u80de\u8fdb\u884c\u4fee\u9970\uff0c\u4ee5\u8bc6\u522b\u548c\u6d88\u9664\u8868\u8fbeBCMA\u7684\u7ec6\u80de\u3002BCMA\u4e3b\u8981\u8868\u8fbe\u4e8e\u6076\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624B\u7ec6\u80de\u8c31\u7cfb\u3001\u665a\u671fB\u7ec6\u80de\u548c\u6d46\u7ec6\u80de\u7684\u8868\u9762\u3002\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u7684CAR\u86cb\u767d\u5177\u6709\u4e24\u79cd\u9776\u5411BCMA\u5355\u57df\u6297\u4f53\uff0c\u5bf9\u8868\u8fbeBCMA\u7684\u7ec6\u80de\u5177\u6709\u9ad8\u4eb2\u548c\u529b\uff0c\u5728\u4e0e\u8868\u8fbeBCMA\u7684\u7ec6\u80de\u7ed3\u5408\u540e\uff0cCAR\u53ef\u4fc3\u8fdbT\u7ec6\u80de\u6d3b\u5316\u3001\u6269\u589e\uff0c\u7ee7\u800c\u6e05\u9664\u9776\u7ec6\u80de[1]\u3002<\/p>\n

2017\u5e7412\u6708\uff0c\u4f20\u5947\u751f\u7269\u4e0e\u5f3a\u751f\u65d7\u4e0b\u6768\u68ee\u516c\u53f8\u8fbe\u6210\u5168\u7403\u72ec\u5bb6\u8bb8\u53ef\u548c\u5408\u4f5c\u534f\u8bae\uff0c\u4ee5\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u30022022\u5e742\u6708\uff0c\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u83b7\u5f97\u7f8e\u56fd\u98df\u54c1\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\uff08FDA\uff09\u6279\u51c6\u4e0a\u5e02\uff0c\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u6216\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u6210\u4eba\u60a3\u8005\uff0c\u5546\u54c1\u540d\u4e3aCARVYKTI\u00ae\u30022024\u5e744\u6708\uff0c\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u9002\u5e94\u75c7\u8fdb\u4e00\u6b65\u6269\u5927\u81f3\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e00\u7ebf\u6cbb\u7597\uff0c\u5305\u62ec\u86cb\u767d\u9176\u4f53\u6291\u5236\u5242\uff08PI\uff09\u548c\u514d\u75ab\u8c03\u8282\u5242\uff08IMiD\uff09\u4e14\u5bf9\u6765\u90a3\u5ea6\u80fa\u8010\u836f\u7684\u590d\u53d1\u6216\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u7684\u4e8c\u7ebf\u6cbb\u7597\u3002<\/p>\n

2022\u5e745\u6708\uff0c\u6b27\u76df\u59d4\u5458\u4f1a\u6388\u4e88CARVYKTI\u00ae\u9644\u6761\u4ef6\u4e0a\u5e02\u8bb8\u53ef\uff0c\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u6210\u4eba\u60a3\u8005\uff1b\u540c\u5e749\u6708\u83b7\u65e5\u672c\u539a\u751f\u52b3\u52a8\u7701\u6279\u51c6\u3002\u8be5\u4ea7\u54c1\u66fe\u4e8e2019\u5e7412\u6708\u5728\u7f8e\u56fd\u548c2020\u5e748\u6708\u5728\u4e2d\u56fd\u83b7\u5f97\u7a81\u7834\u6027\u7597\u6cd5\u8ba4\u5b9a\uff0c\u5e76\u4e8e 2019\u5e744\u6708\u83b7\u5f97\u6b27\u76df\u59d4\u5458\u4f1a\u4f18\u5148\u836f\u7269\u8d44\u683c\u8ba4\u5b9a\u3002\u7f8e\u56fdFDA\u3001\u6b27\u6d32EMA\u548c\u65e5\u672cPMDA\u5206\u522b\u4e8e2019\u5e742\u6708\u30012020\u5e742\u6708\u53ca2020\u5e746\u6708\u6388\u4e88\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u5b64\u513f\u836f\u8d44\u683c\u8ba4\u5b9a\u30022022\u5e743\u6708\uff0c\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\u7684\u5b64\u513f\u836f\u54c1\u59d4\u5458\u4f1a\u4e00\u81f4\u5efa\u8bae\uff0c\u6839\u636e\u4e34\u5e8a\u6570\u636e\uff08\u6cbb\u7597\u540e\u5b8c\u5168\u7f13\u89e3\u7387\u6709\u6240\u6539\u5584\u4e14\u6301\u7eed\u5b58\u5728\uff09\u7ef4\u6301\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u7684\u5b64\u513f\u836f\u8ba4\u5b9a\u3002<\/p>\n

\n \u5173\u4e8e
\n CARTITUDE-4\n <\/p>\n

CARTITUDE-4 (NCT04181827<\/a>) \u662f\u4e00\u9879\u6b63\u5728\u8fdb\u884c\u7684\u56fd\u9645\u591a\u4e2d\u5fc3\u3001\u968f\u673a\u3001\u5f00\u653e\u6807\u7b7e\u76843\u671f\u7814\u7a76\uff0c\u65e8\u5728\u8bc4\u4f30\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u4e0e\u6cca\u9a6c\u5ea6\u80fa\u3001\u787c\u66ff\u4f50\u7c73\u548c\u5730\u585e\u7c73\u677e\uff08PVd\uff09\u6216\u8fbe\u96f7\u59a5\u5c24\u5355\u6297\u3001\u6cca\u9a6c\u5ea6\u80fa\u548c\u5730\u585e\u7c73\u677e\uff08DPd\uff09\u5728\u65e2\u5f80\u63a5\u53d7\u8fc7\u4e00\u81f3\u4e09\u7ebf\u6cbb\u7597\uff08\u5305\u62ec\u4e00\u79cdPI\u548c\u4e00\u79cdIMiD\uff09\u7684\u590d\u53d1\u6216\u6765\u90a3\u5ea6\u80fa\u8010\u836f\u7684\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u6210\u4eba\u60a3\u8005\u4e2d\u7684\u7597\u6548\u548c\u5b89\u5168\u6027\u3002[2]<\/p>\n

\n \u5173\u4e8e
\n CARTITUDE-1\n <\/p>\n

CARTITUDE-1\uff08NCT03548207<\/a>\uff09\u662f\u4e00\u98791b\/2\u671f\u3001\u5f00\u653e\u6807\u7b7e\u3001\u591a\u4e2d\u5fc3\u7814\u7a76\uff0c\u65e8\u5728\u8bc4\u4f30\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u5728\u590d\u53d1\u6216\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u6210\u4eba\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u548c\u6709\u6548\u6027\u3002\u8be5\u7814\u7a76\u5165\u7ec4\u60a3\u8005\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e09\u7ebf\u7597\u6cd5\uff08\u5305\u62ec\u86cb\u767d\u9176\u4f53\u6291\u5236\u5242 [PI]\u3001\u514d\u75ab\u8c03\u8282\u5242 [IMiD] \u548c\u6297CD38\u5355\u514b\u9686\u6297\u4f53\uff09\u6216\u5bf9PI\u3001IMiD\u53cc\u91cd\u8010\u836f\uff0c \u4e14\u5728\u6700\u8fd1\u4e00\u6b21\u6cbb\u7597\u5f00\u59cb\u540e12\u4e2a\u6708\u5185\u51fa\u73b0\u75be\u75c5\u8fdb\u5c55\u30021b\u671f\u7814\u7a76\u7684\u4e3b\u8981\u76ee\u6807\u662f\u8bc4\u4f30\u836f\u7269\u5b89\u5168\u6027\u5e76\u901a\u8fc7LCAR-B38M CAR-T\u7ec6\u80de\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\uff08LEGEND-2\u7814\u7a76\uff09\u7684\u6570\u636e\u6765\u786e\u8ba42\u671f\u63a8\u8350\u5242\u91cf\uff0c 2\u671f\u7814\u7a76\u8fdb\u4e00\u6b65\u8bc4\u4f30\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\u7684\u7597\u6548\uff0c\u4ee5\u603b\u7f13\u89e3\u7387\u4e3a\u4e3b\u8981\u7ec8\u70b9\u3002[3]<\/p>\n

\n \u5173\u4e8e
\n LUCAR-G39D\n <\/p>\n

\n NCT06395870<\/a>\u662f\u4e00\u9879I\u671f\u3001\u5f00\u653e\u6807\u7b7e\u7684\u4e34\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8bc4\u4f30\u9776\u5411CD19\/CD20\u7684\u53cc\u9776\u70b9\u7ec6\u80de\u5236\u5242LUCAR-G39D\u5728\u590d\u53d1\u6216\u96be\u6cbb\u6027B\u7ec6\u80de\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08NHL\uff09\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u8010\u53d7\u6027\u548c\u6709\u6548\u6027\u3002[4]<\/p>\n

\n \u5173\u4e8e\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\n <\/p>\n

\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u88ab\u8ba4\u4e3a\u662f\u4e0d\u53ef\u6cbb\u6108\u7684\u8840\u6db2\u80bf\u7624\uff0c\u662f\u7531\u4e8e\u9aa8\u9ad3\u4e2d\u7684\u6d46\u7ec6\u80de\u8fc7\u5ea6\u589e\u6b96\u5bfc\u81f4\u7684\u6076\u6027\u75be\u75c5\u3002[5]\u9884\u8ba12024\u5e74\u7f8e\u56fd\u5c06\u6709\u8d85\u8fc735000\u4eba\u88ab\u8bca\u65ad\u4e3a\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff0c\u8d85\u8fc712000\u4eba\u6b7b\u4e8e\u8be5\u75be\u75c5\u3002[6]\u867d\u7136\u4e00\u4e9b\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u65e0\u660e\u663e\u75c7\u72b6\uff0c\u662f\u7531\u4e8e\u51fa\u73b0\u75c7\u72b6\u800c\u88ab\u786e\u8bca\uff0c\u8fd9\u4e9b\u75c7\u72b6\u53ef\u80fd\u5305\u62ec\u9aa8\u75c5\u3001\u4f4e\u8840\u7ec6\u80de\u8ba1\u6570\u5f02\u5e38\u3001\u8840\u9499\u5347\u9ad8\u3001\u80be\u810f\u95ee\u9898\u6216\u611f\u67d3\u7b49\u3002[7]<\/p>\n

\n \u5173\u4e8e\u4f20\u5947\u751f\u7269\n <\/p>\n

\u4f20\u5947\u751f\u7269\uff08Legend Biotech\uff09\u662f\u5168\u7403\u6700\u5927\u7684\u72ec\u7acb\u7ec6\u80de\u7597\u6cd5\u516c\u53f8\uff0c\u62e5\u6709\u903e2800\u540d\u5458\u5de5\uff0c\u81f4\u529b\u4e8e\u5f00\u53d1\u80fd\u591f\u6539\u53d8\u764c\u75c7\u6cbb\u7597\u683c\u5c40\u7684\u7a81\u7834\u6027\u7597\u6cd5\u3002\u516c\u53f8\u4e0e\u5408\u4f5c\u4f19\u4f34\u5f3a\u751f\uff08Johnson & Johnson\uff09\u5171\u540c\u5f00\u53d1\u5e76\u5546\u4e1a\u5316\u7684CARVYKTI\u00ae\uff0c\u662f\u4e00\u6b3e\u7528\u4e8e\u6cbb\u7597\u590d\u53d1\u6216\u96be\u6cbb\u6027\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u7684\u4e00\u6b21\u6027\u7597\u6cd5\uff0c\u6b63\u5f15\u9886\u7740CAR-T\u7ec6\u80de\u6cbb\u7597\u9886\u57df\u7684\u9769\u547d\u3002\u516c\u53f8\u603b\u90e8\u4f4d\u4e8e\u7f8e\u56fd\uff0c\u901a\u8fc7\u52a0\u5f3a\u9886\u5bfc\u529b\u5efa\u8bbe\uff0c\u6784\u5efa\u7aef\u5230\u7aef\u7684\u7ec6\u80de\u6cbb\u7597\u4f53\u7cfb\uff0c\u4ee5\u63d0\u5347CARVYKTI\u00ae\u7684\u60a3\u8005\u53ef\u53ca\u6027\u5e76\u5145\u5206\u6316\u6398\u5176\u6cbb\u7597\u6f5c\u529b\u3002\u516c\u53f8\u8ba1\u5212\u4ee5\u6b64\u5e73\u53f0\u4e3a\u57fa\u7840\uff0c\u6301\u7eed\u63a8\u52a8\u5176\u524d\u6cbf\u7ec6\u80de\u6cbb\u7597\u7ba1\u7ebf\u4e2d\u7684\u521b\u65b0\u7814\u53d1\u3002<\/p>\n

\u66f4\u591a\u4fe1\u606f\u8bf7\u8bbf\u95eewww.legendbiotech.com<\/a>.<\/p>\n

\n \u524d\u77bb\u6027\u8bf4\u660e\n <\/p>\n

\n \u672c\u65b0\u95fb\u7a3f\u4e2d\u5173\u4e8e\u672a\u6765\u9884\u671f\u3001\u8ba1\u5212\u548c\u524d\u666f\u7684\u9648\u8ff0\uff0c\u4ee5\u53ca\u5173\u4e8e\u975e\u5386\u53f2\u4e8b\u5b9e\u4e8b\u9879\u7684\u4efb\u4f55\u5176\u4ed6\u9648\u8ff0\uff0c\u5747\u6784\u62101995\u5e74\u300a\u79c1\u4eba\u8bc1\u5238\u8bc9\u8bbc\u6539\u9769\u6cd5\u6848\u300b\u6240\u6307\u7684\u300c\u524d\u77bb\u6027\u9648\u8ff0\u300d\u3002\u8fd9\u4e9b\u9648\u8ff0\u5305\u62ec\u4f46\u4e0d\u9650\u4e8e\uff1a\u4e0e\u4f20\u5947\u751f\u7269\u7684\u6218\u7565\u76ee\u6807\u53ca\u5176\u5019\u9009\u4ea7\u54c1\u6f5c\u5728\u76ca\u5904\u76f8\u5173\u7684\u8868\u8ff0\u3002\u8bf8\u5982\u300c\u9884\u671f\u300d\u3001\u300c\u76f8\u4fe1\u300d\u3001\u300c\u7ee7\u7eed\u300d\u3001\u300c\u53ef\u80fd\u300d\u3001\u300c\u4f30\u8ba1\u300d\u3001\u300c\u9884\u8ba1\u300d\u3001\u300c\u6253\u7b97\u300d\u3001\u300c\u6216\u8bb8\u300d\u3001\u300c\u8ba1\u5212\u300d\u3001\u300c\u6f5c\u529b\u300d\u3001\u300c\u9884\u6d4b\u300d\u3001\u300c\u9879\u76ee\u300d\u3001\u300c\u5e94\u8be5\u300d\u3001\u300c\u76ee\u6807\u300d\u3001\u300c\u5c06\u300d\u3001\u300c\u4f1a\u300d\u548c\u7c7b\u4f3c\u8868\u8fbe\u65e8\u5728\u8bc6\u522b\u524d\u77bb\u6027\u9648\u8ff0\uff0c\u4f46\u5e76\u975e\u6240\u6709\u524d\u77bb\u6027\u9648\u8ff0\u90fd\u5305\u542b\u8fd9\u4e9b\u8bc6\u522b\u8bcd\u3002\u7531\u4e8e\u5404\u79cd\u91cd\u8981\u56e0\u7d20\uff0c\u5b9e\u9645\u7ed3\u679c\u53ef\u80fd\u4e0e\u6b64\u7c7b\u524d\u77bb\u6027\u9648\u8ff0\u6240\u6307\u7684\u7ed3\u679c\u5b58\u5728\u91cd\u5927\u5dee\u5f02\u3002\u4f20\u5947\u751f\u7269\u7684\u9884\u671f\u53ef\u80fd\u4f1a\u53d7\u5230\uff08\u5176\u4e2d\u5305\u62ec\uff09\u4ee5\u4e0b\u56e0\u7d20\u7684\u5f71\u54cd\uff1a\u65b0\u836f\u5f00\u53d1\u6240\u6d89\u53ca\u7684\u4e0d\u786e\u5b9a\u6027\uff1b\u610f\u5916\u7684\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\uff0c\u5305\u62ec\u5bf9\u73b0\u6709\u4e34\u5e8a\u6570\u636e\u6216\u610f\u5916\u7684\u65b0\u4e34\u5e8a\u6570\u636e\u8fdb\u884c\u989d\u5916\u5206\u6790\u7684\u7ed3\u679c\uff1b\u610f\u5916\u7684\u76d1\u7ba1\u884c\u52a8\u6216\u5ef6\u8bef\uff0c\u5305\u62ec\u8981\u6c42\u63d0\u4f9b\u989d\u5916\u7684\u5b89\u5168\u6027\u548c\/\u6216\u6709\u6548\u6027\u6570\u636e\u6216\u6570\u636e\u5206\u6790\uff0c\u6216\u653f\u5e9c\u76d1\u7ba1\u653f\u7b56\u53d8\u5316\uff1b\u56e0\u7b2c\u4e09\u65b9\u5408\u4f5c\u4f19\u4f34\u91c7\u53d6\u7684\u884c\u52a8\u6216\u672a\u80fd\u91c7\u53d6\u884c\u52a8\u800c\u5bfc\u81f4\u7684\u610f\u5916\u5ef6\u8fdf\uff1b\u4f20\u5947\u751f\u7269\u7684\u4e13\u5229\u6216\u5176\u4ed6\u4e13\u6709\u77e5\u8bc6\u4ea7\u6743\u4fdd\u62a4\u53d7\u5230\u6311\u6218\u800c\u4ea7\u751f\u7684\u4e0d\u786e\u5b9a\u6027\uff0c\u5305\u62ec\u7f8e\u56fd\u8bc9\u8bbc\u8fc7\u7a0b\u4e2d\u6d89\u53ca\u7684\u4e0d\u786e\u5b9a\u6027\uff1b\u653f\u5e9c\u3001\u884c\u4e1a\u548c\u4e00\u822c\u4ea7\u54c1\u5b9a\u4ef7\u53ca\u5176\u4ed6\u653f\u6cbb\u538b\u529b\uff1b\u4ee5\u53ca\u4f20\u5947\u751f\u7269\u4e8e2025\u5e743\u670811\u65e5\u5411\u7f8e\u56fd\u8bc1\u5238\u4ea4\u6613\u59d4\u5458\u4f1a\u63d0\u4ea4\u768420-F\u8868\u683c\u5e74\u5ea6\u62a5\u544a\u7684\u300c\u98ce\u9669\u56e0\u7d20\u300d\u90e8\u5206\u6240\u8ba8\u8bba\u7684\u5176\u4ed6\u56e0\u7d20\u3002\u5982\u679c\u4ee5\u4e0a\u4e00\u9879\u6216\u591a\u9879\u98ce\u9669\u6216\u4e0d\u786e\u5b9a\u6027\u6210\u4e3a\u73b0\u5b9e\uff0c\u6216\u8005\u5982\u679c\u57fa\u672c\u5047\u8bbe\u88ab\u8bc1\u660e\u4e0d\u6210\u7acb\uff0c\u5b9e\u9645\u7ed3\u679c\u53ef\u80fd\u4e0e\u672c\u65b0\u95fb\u7a3f\u4e2d\u6240\u8ff0\u7684\u9884\u671f\u3001\u76f8\u4fe1\u3001\u4f30\u8ba1\u6216\u9884\u8ba1\u7684\u7ed3\u679c\u5b58\u5728\u91cd\u5927\u5dee\u5f02\u3002\u672c\u65b0\u95fb\u7a3f\u4e2d\u5305\u542b\u7684\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u4ec5\u4ee3\u8868\u622a\u81f3\u672c\u65b0\u95fb\u7a3f\u53d1\u5e03\u4e4b\u65e5\u7684\u60c5\u51b5\u3002\u4f20\u5947\u751f\u7269\u660e\u786e\u58f0\u660e\uff0c\u65e0\u8bba\u662f\u7531\u4e8e\u65b0\u4fe1\u606f\u3001\u672a\u6765\u4e8b\u4ef6\u8fd8\u662f\u5176\u4ed6\u539f\u56e0\uff0c\u5747\u4e0d\u627f\u62c5\u66f4\u65b0\u4efb\u4f55\u524d\u77bb\u6027\u9648\u8ff0\u7684\u4e49\u52a1\u3002\n <\/p>\n

\n \u672c\u65b0\u95fb\u7a3f\u4e3a\u4e2d\u6587\u7ffb\u8bd1\u7248\uff0c\u5982\u4e2d\u82f1\u6587\u7248\u672c\u6709\u4efb\u4f55\u4e0d\u4e00\u81f4\u7684\u5730\u65b9\uff0c\u5e94\u4ee5\u516c\u53f8\u5b98\u7f51\u53d1\u5e03\u7684\u82f1\u6587\u539f\u7a3f\uff08
\n https:\/\/investors.legendbiotech.com\/press-releases\/
\n \uff09\u4e3a\u51c6\u3002\n <\/p>\n

\n \u5a92\u4f53\u8054\u7edc\uff1a
\n PR@legendbiotech.cn<\/a>\u00a0<\/p>\n

\n \u53c2\u8003\u6765\u6e90\uff1a\n <\/p>\n

\n

\n
\n 1 CARVYKTI\u2122 Prescribing Information. Horsham, PA: Janssen Biotech, Inc.<\/span>\n <\/p>\n

\n
\n 2\u00a0ClinicalTrials.Gov. A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4). https:\/\/www.clinicaltrials.gov\/study\/NCT04181827<\/a>. Accessed March 2024.<\/span>\n <\/p>\n

\n
\n 3\u00a0ClinicalTrials.gov<\/a>. A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma (CARTITUDE-1). Available at:\u00a0https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03548207<\/a>\u00a0Accessed\u00a0October 2022.<\/span>\n <\/p>\n

\n
\n 4\u00a0ClinicalTrials.gov<\/a>. Targeting CD19\/CD20 Dual-targeted Cell in Patients With Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06395870<\/a> Accessed November 2024.<\/span>\n <\/p>\n

\n
\n 5\u00a0American Cancer Society. “What is Multiple Myeloma?”. Available at: https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/what-is-multiple-myeloma.html<\/a>. Accessed March 2024.<\/span>\n <\/p>\n

\n
\n 6\u00a0American Cancer Society. “Key Statistics About Multiple Myeloma.” Available at: https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statistics.html<\/a>. Accessed March 2024<\/span>\n <\/p>\n

\n
\n 7 American Cancer Society. Multiple myeloma: early detection, diagnosis, and staging. Available at: https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8740.00.pdf<\/a>. Accessed March 2023.<\/span>\n <\/p>\n<\/div>\n

\u00a0<\/p>\n

SOURCE \u4f20\u5947\u751f\u7269<\/p>","protected":false},"excerpt":{"rendered":"

2\u9879\u53e3\u5934\u62a5\u544a\u4e0e7\u9879\u58c1\u62a5\u5c55\u793a\u8fdb\u4e00\u6b65\u652f\u6301CARVYKTI\u00ae\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9886\u57df\u7684\u7814\u53d1\u5b9e\u529b \u5f02\u4f53 CAR-T\u7ec6\u80de\u7597\u6cd5\u6cbb\u7597\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u7684\u9996\u6b21\u4eba\u4f53I\u671f\u4e34\u5e8a\u6570\u636e\u5c06\u4f5c\u4e3a\u53e3\u5934\u62a5\u544a\u91cd\u70b9\u5c55\u793a \u7f8e\u56fd\u65b0\u6cfd\u897f\u5dde\u8428\u9ed8\u585e\u7279 2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ — \u5168\u7403\u7ec6\u80de\u7597\u6cd5\u9886\u5bfc\u8005\u4f20\u5947\u751f\u7269\u79d1\u6280\u516c\u53f8\uff08NASDAQ\uff1aLEGN\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5c06\u5728\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u4e0a\u901a\u8fc7\u4e24\u9879\u53e3\u5934\u62a5\u544a\u548c\u4e03\u9879\u58c1\u62a5\u91cd\u70b9\u5c55\u793aCARVYKTI\u00ae\uff08cilta-cel\uff1b\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\uff09\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9886\u57df\u7684\u6700\u65b0\u6570\u636e\u3002\u672c\u5c4a\u5e74\u4f1a\u5c06\u4e8e2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u56fd\u4f5b\u7f57\u91cc\u8fbe\u5dde\u5965\u5170\u591a\u4e3e\u884c\u3002 \u9664CARVYKTI\u76f8\u5173\u6570\u636e\u5916\uff0c\u516c\u53f8\u8fd8\u5c06\u5c31\u5176\u5728\u7814\u7684\u9776\u5411CD20\/CD19\u53cc\u9776\u70b9\u901a\u7528\u578bCAR-\u03b3\u03b4T\u7ec6\u80de\u7597\u6cd5Lucar-G39D\u8fdb\u884c\u53e3\u5934\u62a5\u544a\uff0c\u8be5\u7597\u6cd5\u76ee\u524d\u6b63\u9488\u5bf9\u590d\u53d1\u6216\u96be\u6cbb\u6027B\u7ec6\u80de\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08NHL\uff09\u60a3\u8005\u5f00\u5c55\u4e34\u5e8a\u8bc4\u4f30\u3002 \u4f20\u5947\u751f\u7269\u9996\u5e2d\u6267\u884c\u5b98\u9ec4\u9896\u535a\u58eb\u8868\u793a\uff1a”\u6211\u4eec\u5f88\u81ea\u8c6a\u5730\u770b\u5230\uff0c\u4eca\u5e74ASH\u5e74\u4f1a\u6240\u5c55\u793a\u7684\u6570\u636e\u66f4\u52a0\u6df1\u5165\u800c\u5e7f\u6cdb\uff0c\u8fd9\u5145\u5206\u4f53\u73b0\u4e86\u6211\u4eec\u7ec6\u80de\u7597\u6cd5\u9879\u76ee\u7684\u6301\u7eed\u521b\u65b0\u548c\u4e34\u5e8a\u5f71\u54cd\u529b\u3002\u672c\u5c4a\u4f1a\u8bae\u4e0a\u67099\u7bc7\u6458\u8981\u91cd\u70b9\u4ecb\u7ecd\u4e86CARVYKTI\uff0c\u8fd9\u4e9b\u7814\u7a76\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u5176\u5728\u7597\u6548\u6301\u4e45\u6027\u3001\u6301\u7eed\u4f18\u5316\u7684\u5b89\u5168\u6027\u7279\u5f81\u4ee5\u53ca\u771f\u5b9e\u4e16\u754c\u7597\u6548\u65b9\u9762\u7684\u8868\u73b0\uff0c\u4e3aCAR-T\u7597\u6cd5\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u66f4\u65e9\u7ebf\u6cbb\u7597\u4e2d\u7684\u5e94\u7528\u63d0\u4f9b\u4e86\u6709\u529b\u652f\u6301\u3002\u6b64\u5916\uff0cLucar-G39D\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\u6570\u636e\u5f70\u663e\u4e86\u6211\u4eec\u6b63\u5728\u6301\u7eed\u52aa\u529b\u5c06\u6211\u4eec\u7684\u7814\u53d1\u7ba1\u7ebf\u6269\u5c55\u5230\u9488\u5bf9B\u7ec6\u80de\u6076\u6027\u80bf\u7624\u60a3\u8005\u7684\u4e0b\u4e00\u4ee3\u5f02\u4f53\u7ec6\u80de\u7597\u6cd5\u3002” CARVYKTI\u662f\u5168\u7403\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e00\u7ebf\u6cbb\u7597\u7684\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u7684BCMA \u9776\u5411CAR-T\u7ec6\u80de\u7597\u6cd5\u3002\u76ee\u524dCARVYKTI\u5df2\u5728\u5168\u740314\u4e2a\u56fd\u5bb6\u4e0a\u5e02\uff0c\u8fc4\u4eca\u5df2\u6cbb\u7597\u8d85\u8fc79,000\u540d\u60a3\u8005\u3002 \u4f1a\u8bae\u6458\u8981\u5217\u8868\u5982\u4e0b\uff1a ASH Presentations (December 6-9, 2025) CARVYKTI \u00ae \u6458\u8981\u7f16\u53f7 \u6807\u9898 \u4f1a\u8bae\u4fe1\u606f \u6458\u8981#94 \u53e3\u5934\u62a5\u544a Long-Term Progression-Free Survival Benefit With Ciltacabtagene Autoleucel in Standard-Risk Relapsed\/Refractory Multiple Myeloma \u4f1a\u8bae\u540d\u79f0\uff1a653. \u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a \u4f18\u5316\u9aa8\u9ad3\u7624\u7684\u514d\u75ab\u7597\u6cd5\u2014\u2014\u4eceT\u7ec6\u80de\u9002\u5e94\u6027\u5230\u4e34\u5e8a\u7ed3\u5c40\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u53489:30 – \u4e0a\u534811:00\u62a5\u544a\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u534810:15 – \u4e0a\u534810:30 \u6458\u8981#92 \u53e3\u5934\u62a5\u544a Earlier Use of Ciltacabtagene Autoleucel (Cilta-cel) Is Associated With […]<\/p>\n","protected":false},"author":0,"featured_media":17736,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-17735","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"\n\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a - Money Compass CN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/moneycompass.com.my\/cn\/\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a - Money Compass CN\" \/>\n<meta property=\"og:description\" content=\"2\u9879\u53e3\u5934\u62a5\u544a\u4e0e7\u9879\u58c1\u62a5\u5c55\u793a\u8fdb\u4e00\u6b65\u652f\u6301CARVYKTI\u00ae\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9886\u57df\u7684\u7814\u53d1\u5b9e\u529b \u5f02\u4f53 CAR-T\u7ec6\u80de\u7597\u6cd5\u6cbb\u7597\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u7684\u9996\u6b21\u4eba\u4f53I\u671f\u4e34\u5e8a\u6570\u636e\u5c06\u4f5c\u4e3a\u53e3\u5934\u62a5\u544a\u91cd\u70b9\u5c55\u793a \u7f8e\u56fd\u65b0\u6cfd\u897f\u5dde\u8428\u9ed8\u585e\u7279 2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ — \u5168\u7403\u7ec6\u80de\u7597\u6cd5\u9886\u5bfc\u8005\u4f20\u5947\u751f\u7269\u79d1\u6280\u516c\u53f8\uff08NASDAQ\uff1aLEGN\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5c06\u5728\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u4e0a\u901a\u8fc7\u4e24\u9879\u53e3\u5934\u62a5\u544a\u548c\u4e03\u9879\u58c1\u62a5\u91cd\u70b9\u5c55\u793aCARVYKTI\u00ae\uff08cilta-cel\uff1b\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\uff09\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9886\u57df\u7684\u6700\u65b0\u6570\u636e\u3002\u672c\u5c4a\u5e74\u4f1a\u5c06\u4e8e2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u56fd\u4f5b\u7f57\u91cc\u8fbe\u5dde\u5965\u5170\u591a\u4e3e\u884c\u3002 \u9664CARVYKTI\u76f8\u5173\u6570\u636e\u5916\uff0c\u516c\u53f8\u8fd8\u5c06\u5c31\u5176\u5728\u7814\u7684\u9776\u5411CD20\/CD19\u53cc\u9776\u70b9\u901a\u7528\u578bCAR-\u03b3\u03b4T\u7ec6\u80de\u7597\u6cd5Lucar-G39D\u8fdb\u884c\u53e3\u5934\u62a5\u544a\uff0c\u8be5\u7597\u6cd5\u76ee\u524d\u6b63\u9488\u5bf9\u590d\u53d1\u6216\u96be\u6cbb\u6027B\u7ec6\u80de\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08NHL\uff09\u60a3\u8005\u5f00\u5c55\u4e34\u5e8a\u8bc4\u4f30\u3002 \u4f20\u5947\u751f\u7269\u9996\u5e2d\u6267\u884c\u5b98\u9ec4\u9896\u535a\u58eb\u8868\u793a\uff1a”\u6211\u4eec\u5f88\u81ea\u8c6a\u5730\u770b\u5230\uff0c\u4eca\u5e74ASH\u5e74\u4f1a\u6240\u5c55\u793a\u7684\u6570\u636e\u66f4\u52a0\u6df1\u5165\u800c\u5e7f\u6cdb\uff0c\u8fd9\u5145\u5206\u4f53\u73b0\u4e86\u6211\u4eec\u7ec6\u80de\u7597\u6cd5\u9879\u76ee\u7684\u6301\u7eed\u521b\u65b0\u548c\u4e34\u5e8a\u5f71\u54cd\u529b\u3002\u672c\u5c4a\u4f1a\u8bae\u4e0a\u67099\u7bc7\u6458\u8981\u91cd\u70b9\u4ecb\u7ecd\u4e86CARVYKTI\uff0c\u8fd9\u4e9b\u7814\u7a76\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u5176\u5728\u7597\u6548\u6301\u4e45\u6027\u3001\u6301\u7eed\u4f18\u5316\u7684\u5b89\u5168\u6027\u7279\u5f81\u4ee5\u53ca\u771f\u5b9e\u4e16\u754c\u7597\u6548\u65b9\u9762\u7684\u8868\u73b0\uff0c\u4e3aCAR-T\u7597\u6cd5\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u66f4\u65e9\u7ebf\u6cbb\u7597\u4e2d\u7684\u5e94\u7528\u63d0\u4f9b\u4e86\u6709\u529b\u652f\u6301\u3002\u6b64\u5916\uff0cLucar-G39D\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\u6570\u636e\u5f70\u663e\u4e86\u6211\u4eec\u6b63\u5728\u6301\u7eed\u52aa\u529b\u5c06\u6211\u4eec\u7684\u7814\u53d1\u7ba1\u7ebf\u6269\u5c55\u5230\u9488\u5bf9B\u7ec6\u80de\u6076\u6027\u80bf\u7624\u60a3\u8005\u7684\u4e0b\u4e00\u4ee3\u5f02\u4f53\u7ec6\u80de\u7597\u6cd5\u3002” CARVYKTI\u662f\u5168\u7403\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e00\u7ebf\u6cbb\u7597\u7684\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u7684BCMA \u9776\u5411CAR-T\u7ec6\u80de\u7597\u6cd5\u3002\u76ee\u524dCARVYKTI\u5df2\u5728\u5168\u740314\u4e2a\u56fd\u5bb6\u4e0a\u5e02\uff0c\u8fc4\u4eca\u5df2\u6cbb\u7597\u8d85\u8fc79,000\u540d\u60a3\u8005\u3002 \u4f1a\u8bae\u6458\u8981\u5217\u8868\u5982\u4e0b\uff1a ASH Presentations (December 6-9, 2025) CARVYKTI \u00ae \u6458\u8981\u7f16\u53f7 \u6807\u9898 \u4f1a\u8bae\u4fe1\u606f \u6458\u8981#94 \u53e3\u5934\u62a5\u544a Long-Term Progression-Free Survival Benefit With Ciltacabtagene Autoleucel in Standard-Risk Relapsed\/Refractory Multiple Myeloma \u4f1a\u8bae\u540d\u79f0\uff1a653. \u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a \u4f18\u5316\u9aa8\u9ad3\u7624\u7684\u514d\u75ab\u7597\u6cd5\u2014\u2014\u4eceT\u7ec6\u80de\u9002\u5e94\u6027\u5230\u4e34\u5e8a\u7ed3\u5c40\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u53489:30 – \u4e0a\u534811:00\u62a5\u544a\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u534810:15 – \u4e0a\u534810:30 \u6458\u8981#92 \u53e3\u5934\u62a5\u544a Earlier Use of Ciltacabtagene Autoleucel (Cilta-cel) Is Associated With […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/moneycompass.com.my\/cn\/\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ash\/\" \/>\n<meta property=\"og:site_name\" content=\"Money Compass CN\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T17:28:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/\",\"name\":\"\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a - Money Compass CN\",\"isPartOf\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/11\/image_5019178_528987_Logo-YCiE8v.jpeg\",\"datePublished\":\"2025-11-03T17:28:00+00:00\",\"dateModified\":\"2025-11-03T17:28:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#primaryimage\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/11\/image_5019178_528987_Logo-YCiE8v.jpeg\",\"contentUrl\":\"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/11\/image_5019178_528987_Logo-YCiE8v.jpeg\",\"width\":144,\"height\":60},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/moneycompass.com.my\/cn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/moneycompass.com.my\/cn\/#website\",\"url\":\"https:\/\/moneycompass.com.my\/cn\/\",\"name\":\"Money Compass CN\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a - Money Compass CN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/moneycompass.com.my\/cn\/\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ash\/","og_locale":"en_US","og_type":"article","og_title":"\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a - Money Compass CN","og_description":"2\u9879\u53e3\u5934\u62a5\u544a\u4e0e7\u9879\u58c1\u62a5\u5c55\u793a\u8fdb\u4e00\u6b65\u652f\u6301CARVYKTI\u00ae\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9886\u57df\u7684\u7814\u53d1\u5b9e\u529b \u5f02\u4f53 CAR-T\u7ec6\u80de\u7597\u6cd5\u6cbb\u7597\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u7684\u9996\u6b21\u4eba\u4f53I\u671f\u4e34\u5e8a\u6570\u636e\u5c06\u4f5c\u4e3a\u53e3\u5934\u62a5\u544a\u91cd\u70b9\u5c55\u793a \u7f8e\u56fd\u65b0\u6cfd\u897f\u5dde\u8428\u9ed8\u585e\u7279 2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ — \u5168\u7403\u7ec6\u80de\u7597\u6cd5\u9886\u5bfc\u8005\u4f20\u5947\u751f\u7269\u79d1\u6280\u516c\u53f8\uff08NASDAQ\uff1aLEGN\uff09\u4eca\u65e5\u5ba3\u5e03\uff0c\u516c\u53f8\u5c06\u5728\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a\u4e0a\u901a\u8fc7\u4e24\u9879\u53e3\u5934\u62a5\u544a\u548c\u4e03\u9879\u58c1\u62a5\u91cd\u70b9\u5c55\u793aCARVYKTI\u00ae\uff08cilta-cel\uff1b\u897f\u8fbe\u57fa\u5965\u4ed1\u8d5b\uff09\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u9886\u57df\u7684\u6700\u65b0\u6570\u636e\u3002\u672c\u5c4a\u5e74\u4f1a\u5c06\u4e8e2025\u5e7412\u67086\u65e5\u81f39\u65e5\u5728\u7f8e\u56fd\u4f5b\u7f57\u91cc\u8fbe\u5dde\u5965\u5170\u591a\u4e3e\u884c\u3002 \u9664CARVYKTI\u76f8\u5173\u6570\u636e\u5916\uff0c\u516c\u53f8\u8fd8\u5c06\u5c31\u5176\u5728\u7814\u7684\u9776\u5411CD20\/CD19\u53cc\u9776\u70b9\u901a\u7528\u578bCAR-\u03b3\u03b4T\u7ec6\u80de\u7597\u6cd5Lucar-G39D\u8fdb\u884c\u53e3\u5934\u62a5\u544a\uff0c\u8be5\u7597\u6cd5\u76ee\u524d\u6b63\u9488\u5bf9\u590d\u53d1\u6216\u96be\u6cbb\u6027B\u7ec6\u80de\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\uff08NHL\uff09\u60a3\u8005\u5f00\u5c55\u4e34\u5e8a\u8bc4\u4f30\u3002 \u4f20\u5947\u751f\u7269\u9996\u5e2d\u6267\u884c\u5b98\u9ec4\u9896\u535a\u58eb\u8868\u793a\uff1a”\u6211\u4eec\u5f88\u81ea\u8c6a\u5730\u770b\u5230\uff0c\u4eca\u5e74ASH\u5e74\u4f1a\u6240\u5c55\u793a\u7684\u6570\u636e\u66f4\u52a0\u6df1\u5165\u800c\u5e7f\u6cdb\uff0c\u8fd9\u5145\u5206\u4f53\u73b0\u4e86\u6211\u4eec\u7ec6\u80de\u7597\u6cd5\u9879\u76ee\u7684\u6301\u7eed\u521b\u65b0\u548c\u4e34\u5e8a\u5f71\u54cd\u529b\u3002\u672c\u5c4a\u4f1a\u8bae\u4e0a\u67099\u7bc7\u6458\u8981\u91cd\u70b9\u4ecb\u7ecd\u4e86CARVYKTI\uff0c\u8fd9\u4e9b\u7814\u7a76\u8fdb\u4e00\u6b65\u9a8c\u8bc1\u4e86\u5176\u5728\u7597\u6548\u6301\u4e45\u6027\u3001\u6301\u7eed\u4f18\u5316\u7684\u5b89\u5168\u6027\u7279\u5f81\u4ee5\u53ca\u771f\u5b9e\u4e16\u754c\u7597\u6548\u65b9\u9762\u7684\u8868\u73b0\uff0c\u4e3aCAR-T\u7597\u6cd5\u5728\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u66f4\u65e9\u7ebf\u6cbb\u7597\u4e2d\u7684\u5e94\u7528\u63d0\u4f9b\u4e86\u6709\u529b\u652f\u6301\u3002\u6b64\u5916\uff0cLucar-G39D\u7684\u9996\u6b21\u4eba\u4f53\u8bd5\u9a8c\u6570\u636e\u5f70\u663e\u4e86\u6211\u4eec\u6b63\u5728\u6301\u7eed\u52aa\u529b\u5c06\u6211\u4eec\u7684\u7814\u53d1\u7ba1\u7ebf\u6269\u5c55\u5230\u9488\u5bf9B\u7ec6\u80de\u6076\u6027\u80bf\u7624\u60a3\u8005\u7684\u4e0b\u4e00\u4ee3\u5f02\u4f53\u7ec6\u80de\u7597\u6cd5\u3002” CARVYKTI\u662f\u5168\u7403\u9996\u4e2a\u4e14\u552f\u4e00\u83b7\u6279\u7528\u4e8e\u6cbb\u7597\u65e2\u5f80\u81f3\u5c11\u63a5\u53d7\u8fc7\u4e00\u7ebf\u6cbb\u7597\u7684\u591a\u53d1\u6027\u9aa8\u9ad3\u7624\u60a3\u8005\u7684BCMA \u9776\u5411CAR-T\u7ec6\u80de\u7597\u6cd5\u3002\u76ee\u524dCARVYKTI\u5df2\u5728\u5168\u740314\u4e2a\u56fd\u5bb6\u4e0a\u5e02\uff0c\u8fc4\u4eca\u5df2\u6cbb\u7597\u8d85\u8fc79,000\u540d\u60a3\u8005\u3002 \u4f1a\u8bae\u6458\u8981\u5217\u8868\u5982\u4e0b\uff1a ASH Presentations (December 6-9, 2025) CARVYKTI \u00ae \u6458\u8981\u7f16\u53f7 \u6807\u9898 \u4f1a\u8bae\u4fe1\u606f \u6458\u8981#94 \u53e3\u5934\u62a5\u544a Long-Term Progression-Free Survival Benefit With Ciltacabtagene Autoleucel in Standard-Risk Relapsed\/Refractory Multiple Myeloma \u4f1a\u8bae\u540d\u79f0\uff1a653. \u591a\u53d1\u6027\u9aa8\u9ad3\u7624\uff1a\u4e34\u5e8a\u4e0e\u6d41\u884c\u75c5\u5b66\uff1a \u4f18\u5316\u9aa8\u9ad3\u7624\u7684\u514d\u75ab\u7597\u6cd5\u2014\u2014\u4eceT\u7ec6\u80de\u9002\u5e94\u6027\u5230\u4e34\u5e8a\u7ed3\u5c40\u65e5\u671f\/\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u53489:30 – \u4e0a\u534811:00\u62a5\u544a\u65f6\u95f4\uff1a2025\u5e7412\u67086\u65e5\u4e0a\u534810:15 – \u4e0a\u534810:30 \u6458\u8981#92 \u53e3\u5934\u62a5\u544a Earlier Use of Ciltacabtagene Autoleucel (Cilta-cel) Is Associated With […]","og_url":"https:\/\/moneycompass.com.my\/cn\/\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ash\/","og_site_name":"Money Compass CN","article_published_time":"2025-11-03T17:28:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/","url":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/","name":"\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a - Money Compass CN","isPartOf":{"@id":"https:\/\/moneycompass.com.my\/cn\/#website"},"primaryImageOfPage":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#primaryimage"},"image":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#primaryimage"},"thumbnailUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/11\/image_5019178_528987_Logo-YCiE8v.jpeg","datePublished":"2025-11-03T17:28:00+00:00","dateModified":"2025-11-03T17:28:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#primaryimage","url":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/11\/image_5019178_528987_Logo-YCiE8v.jpeg","contentUrl":"https:\/\/moneycompass.com.my\/cn\/wp-content\/uploads\/2025\/11\/image_5019178_528987_Logo-YCiE8v.jpeg","width":144,"height":60},{"@type":"BreadcrumbList","@id":"https:\/\/moneycompass.com.my\/cn\/%e4%bc%a0%e5%a5%87%e7%94%9f%e7%89%a910%e9%a1%b9%e7%a0%94%e7%a9%b6%e6%88%90%e6%9e%9c%e5%b0%86%e4%ba%ae%e7%9b%b8%e7%ac%ac67%e5%b1%8a%e7%be%8e%e5%9b%bd%e8%a1%80%e6%b6%b2%e5%ad%a6%e4%bc%9a%ef%bc%88ash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/moneycompass.com.my\/cn\/"},{"@type":"ListItem","position":2,"name":"\u4f20\u5947\u751f\u726910\u9879\u7814\u7a76\u6210\u679c\u5c06\u4eae\u76f8\u7b2c67\u5c4a\u7f8e\u56fd\u8840\u6db2\u5b66\u4f1a\uff08ASH\uff09\u5e74\u4f1a"}]},{"@type":"WebSite","@id":"https:\/\/moneycompass.com.my\/cn\/#website","url":"https:\/\/moneycompass.com.my\/cn\/","name":"Money Compass CN","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/moneycompass.com.my\/cn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/17735"}],"collection":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/comments?post=17735"}],"version-history":[{"count":0,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/posts\/17735\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media\/17736"}],"wp:attachment":[{"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/media?parent=17735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/categories?post=17735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/moneycompass.com.my\/cn\/wp-json\/wp\/v2\/tags?post=17735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}